News: Portfolio 2009

AMORCYTE REPORTS PHASE I RESULTS OF AMR-001 TO IMPROVE RECOVERY FROM SEVERE HEART ATTACK AT ACC ANNUAL SCIENTIFIC SESSION

First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion

Orlando, Fla, March 30, 2009 –Amorcyte, Inc. (Amorcyte) today announced data from its Phase I clinical trial of AMR-001, the company’s lead product for the treatment of damaged heart muscle following acute myocardial infarction (AMI), that showed a significant relationship between cell dose and biologic effect. This is the first and only study to prospectively define a dose of a purified and potent autologous stem cell therapy (AMR-001) that resulted in a significant improvement in perfusion, a trend towards improved cardiac function and the potential to reduce subsequent adverse cardiac events following AMI. The findings were presented at the American College of Cardiology (ACC) Annual Scientific Session.

 

The 31 patients in the Phase I trial were randomly assigned to an autologous stem cell harvest group